Evolus, Inc. (EOLS) vs Kamada Ltd. (KMDA)

Evolus, Inc. and Kamada Ltd. are both Drug Manufacturers Specialty & Generic companies. Evolus, Inc. and Kamada Ltd. are of similar size ($519.2M and $509.4M). Evolus, Inc. has negative trailing earnings, so its P/E is not meaningful; Kamada Ltd. trades at 22.9×. Evolus, Inc. grew revenue faster over the last twelve months: 13.9% against 13.2%. Kamada Ltd. has the higher net margin (11.6% vs −10.9%) and the higher return on invested capital (8.47% vs −14.5%). Across the 18 metrics below, Kamada Ltd. leads on 10 and Evolus, Inc. on 8.

Valuation

Metric EOLS KMDA Drug Manufacturers Specialty & Generic median
P/E n/m 22.95 20.14
P/S 1.66 2.63 2.25
P/B n/m 1.87 1.90
Price to free cash flow n/m 19.18 16.54
EV/EBITDA n/m 10.33 12.29
EV/Sales 2.02 2.32 2.56
Earnings yield (6.52%) 4.36% (2.99%)
Free cash flow yield (4.17%) 5.21% 0.00%

Profitability

Metric EOLS KMDA Drug Manufacturers Specialty & Generic median
Gross margin 66.74% 40.82% 53.94%
Operating margin (5.90%) 14.51% 0.00%
Net margin (10.85%) 11.60% 0.00%
Free cash flow margin (6.92%) 13.72% 0.00%
Return on equity 138.57% 8.40% (0.40%)
Return on assets (14.40%) 5.92% (3.32%)
Return on invested capital (14.47%) 8.47% 0.00%

Growth

Metric EOLS KMDA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 13.87% 13.17% 10.01%
EPS growth (last fiscal year) 1.23% 40.00% —
Revenue growth, 5-year CAGR 39.36% 6.25% 6.74%
Net income growth, 5-year CAGR 0.00% 3.34% 0.00%

Health

Metric EOLS KMDA Drug Manufacturers Specialty & Generic median
Debt to equity (5.07) 0.02 0.05
Current ratio 1.70 4.06 2.31
Net debt to EBITDA (4.08) (1.59) 0.85

Dividend

Metric EOLS KMDA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric EOLS KMDA Drug Manufacturers Specialty & Generic median
Market cap 519.16m 509.40m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack